News

BioInvent International and ThromboGenics said that the Phase II results demonstrate that TB-402 has superior antithrombotic activity to enoxaparin with comparable safety. Enoxaparin is currently the standard treatment

Synairgen said that the issued patent is part of a patent portfolio owned by the University of Southampton, which is exclusively licensed to Synairgen. Reportedly, laboratory experiments were

SIPO said that as a high growth company with a focus on technology innovation and intellectual property, Renhuang was selected as one of a handful pharmaceutical companies from

As per the restructured agreement, Merck has acquired full control of the development and worldwide commercialisation of Ridaforolimus. Ariad is expected to receive a $50m upfront fee and

The poster is presented at ‘The Power of Programming 2010 International conference on developmental origins of health and disease’ in Munich, Germany. Swedish Orphan Biovitrum claimed that Kiobrina

The study demonstrated that single intravenous doses of 1 and 3mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2mcg for subsequent

Under the agreement, Glenmark is expected to manufacture the FDA approved products exclusively for Taro USA. Taro USA’s branded division, TaroPharma, a division that offers dermatologists and pediatricians

Under the terms of the agreement, Boehringer Ingelheim will pay Micromet an upfront cash payment of approximately $6.6m. Micromet will be eligible to receive development and regulatory milestone

AEZS-108 is doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in